Indivior PLC, a specialty pharmaceutical company headquartered in the United Kingdom, has carved out a unique niche in the healthcare industry by focusing on the treatment of addiction and related mental health disorders. Established in 2014 as a spin-off from Reckitt Benckiser Group PLC, Indivior has since become a global leader in the development and commercialization of medications for opioid use disorder (OUD) and other substance use disorders (SUDs).
At the heart of Indivior’s mission is a commitment to addressing the complex challenges associated with addiction through research, innovation, and advocacy. The company’s flagship product, Suboxone® (buprenorphine and naloxone), is a medication-assisted treatment (MAT) that helps individuals struggling with opioid dependence manage withdrawal symptoms and cravings while reducing the risk of relapse. Suboxone® has been instrumental in revolutionizing addiction treatment by offering a safer and more effective alternative to traditional opioid replacement therapies like methadone.
In addition to Suboxone®, Indivior has expanded its product portfolio to include other medications aimed at treating addiction and related disorders. Sublocade® (buprenorphine extended-release) is a once-monthly injectable formulation of buprenorphine designed to provide sustained relief from opioid cravings, offering patients greater convenience and compliance compared to daily oral medications. Perseris® (risperidone), another innovative product from Indivior, is indicated for the treatment of schizophrenia, providing healthcare providers and patients with a long-acting injectable option for managing this chronic psychiatric condition.
Indivior’s commitment to innovation extends beyond the development of new medications to encompass research into the underlying mechanisms of addiction and the development of holistic treatment approaches. The company invests heavily in clinical research and development, collaborating with leading academic institutions and research organizations to advance scientific knowledge in the field of addiction medicine. By staying at the forefront of scientific discovery, Indivior aims to continuously improve the efficacy and safety of its products while exploring novel therapeutic strategies for addressing addiction and related disorders.
Beyond its focus on research and development, Indivior is actively engaged in advocacy efforts aimed at raising awareness of addiction as a chronic medical condition and promoting access to evidence-based treatment options. The company works closely with policymakers, healthcare providers, patient advocacy groups, and other stakeholders to advocate for policies and programs that support comprehensive addiction treatment and recovery services. Through these efforts, Indivior seeks to reduce the stigma surrounding addiction, increase access to treatment, and improve outcomes for individuals and communities affected by substance use disorders.
As Indivior continues to grow and evolve, its commitment to innovation, advocacy, and patient-centered care remains unwavering. By leveraging its expertise in addiction medicine and its dedication to improving patient outcomes, Indivior is poised to make a meaningful impact on the lives of individuals struggling with addiction and related disorders worldwide.